Can analysts adopt a bullish outlook for Horizon Pharma Public Limited Company (NASDAQ:HZNP)?

February 15, 2018 - By Richard Conner

 Can analysts adopt a bullish outlook for Horizon Pharma Public Limited Company (NASDAQ:HZNP)?
Investors sentiment increased to 1 in Q3 2017. Its up 0.08, from 0.92 in 2017Q2. It increased, as 33 investors sold Horizon Pharma Public Limited Company shares while 50 reduced holdings. 28 funds opened positions while 55 raised stakes. 132.29 million shares or 1.03% more from 130.94 million shares in 2017Q2 were reported.
Barclays Public Limited Liability owns 1.58 million shares. Meeder Asset Management invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Chicago Equity Ptnrs Ltd, a Illinois-based fund reported 136,120 shares. Capstone Invest Advsr Lc holds 13,000 shares or 0.01% of its portfolio. Georgia-based Voya Inv Management Limited Liability Corp has invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Rhenman And Prns Asset Ab holds 4.87% or 3.01M shares. Envestnet Asset Management Inc holds 2,686 shares. California Pub Employees Retirement, a California-based fund reported 325,085 shares. Cim Investment Mangement invested in 0.15% or 32,292 shares. Globeflex Capital Ltd Partnership has 62,393 shares. Ahl Limited Liability Partnership invested in 0.02% or 106,405 shares. 556,229 were accumulated by Great Lakes Advisors Ltd Limited Liability Company. Hl Limited Liability holds 11,600 shares. National Bank Of America De holds 3.12M shares or 0.01% of its portfolio. Lakeview Cap Ltd Liability Corporation owns 29,107 shares or 0.3% of their US portfolio.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Among 13 analysts covering Horizon Pharma (NASDAQ:HZNP), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Horizon Pharma had 55 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Tuesday, November 10. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Neutral” rating given on Tuesday, August 9 by Citigroup. The firm has “Buy” rating given on Monday, October 30 by BMO Capital Markets. The stock has “Buy” rating by Jefferies on Tuesday, August 8. The company was maintained on Tuesday, September 12 by Jefferies. Mizuho maintained the shares of HZNP in report on Tuesday, May 10 with “Buy” rating. The rating was reinitiated by Morgan Stanley on Thursday, December 3 with “Underweight”. The firm has “Buy” rating given on Tuesday, June 27 by Stifel Nicolaus. Piper Jaffray maintained the stock with “Buy” rating in Friday, September 8 report. The firm has “Buy” rating by Citigroup given on Monday, November 28. Below is a list of Horizon Pharma Public Limited Company (NASDAQ:HZNP) latest ratings and price target changes.

30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0 Maintain
12/01/2018 Broker: Mizuho Old Rating: Neutral New Rating: Buy Upgrade
30/11/2017 Broker: UBS Rating: Buy New Target: $20.0 Maintain
10/11/2017 Broker: Cowen & Co Rating: Buy New Target: $22.0 Maintain
07/11/2017 Broker: Jefferies Rating: Buy Old Target: $16 New Target: $21 Maintain
06/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $17.0 Maintain
30/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $18.0 Maintain
20/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $20.0 Maintain
13/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $18.0 Maintain
13/10/2017 Broker: Jefferies Rating: Buy New Target: $16.0 Maintain

The stock decreased 0.50% or $0.07 during the last trading session, reaching $14.04. About 538,615 shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 28.13% since February 15, 2017 and is downtrending. It has underperformed by 44.83% the S&P500.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $2.30 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Globenewswire.com which released: “Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial …” on January 29, 2018, also Globenewswire.com with their article: “Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate …” published on January 30, 2018, Globenewswire.com published: “Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers …” on January 08, 2018. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Seekingalpha.com and their article: “Horizon Pharma Plc (HZNP) Q3 2017 Results – Earnings Call Transcript” published on November 06, 2017 as well as Reuters.com‘s news article titled: “Horizon Pharma weighs sale of primary care unit -sources” with publication date: September 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.